This study aimed to assess survival outcomes and analyze the risk factors of first - line gemcitabin / cisplatin chemotherapy in metastatic / recurrent nasopharyngeal carcinoma. Methods: Retrospective and prospective analyses of 56 patients with metastatic / recurrent nasopharyngeal carcinoma diagnosed and treated with first - line gemcitabin / cisplatin chemotherapy at National Cancer Hospital from 01/2018 to 30/10/2021.